Intercept's drug for patients with liver fibrosis due to NASH meets main goal

  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 66%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

REUTERS: Intercept Pharmaceuticals Inc said on Tuesday its treatment testing patients with liver fibrosis due to nonalcoholic steatohepatitis ...

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patientsNektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Liver cancer top cause of cancer death among men in their 40s and 50sThe statistics about hepatocellular carcinoma (HCC), the most common type of primary liver cancer, are troubling. Eighty per cent of all the cases in the world occur in Asia, and it has come to be known as an 'Asian disease'. HCC is the third most common cause of...
Source: thenewpaper - 🏆 7. / 63 Read more »

Health Minister Gan: Patients affected in HIV leak can sue MOH for data lossHealth Minister Gan Kim Yong said in Parliament on Tuesday, February 12, that the 14,200 HIV patients who were affected by the massive data breach of confidential data may choose to take civil action against the Ministry of Health (MOH). Sorry ahh Mr. Health minister. I think yr political career is over😄 Don't despair though. They might find you another high paying job in perhaps a Temasek entity😂
Source: IndependentSG - 🏆 2. / 72 Read more »